Selvita - your integrated drug discovery partner of choice

The largest drug
discovery company
in the CEE region

Your integrated drug
discovery partner of choice

Developing breakthrough
therapies in oncology

Delivering comprehensive
research solutions to biotech
and pharma

Krakow, Poland – 5 June 2019 – Selvita, drug discovery and development partner for the pharmaceutical and biotechnology industries, will...

Krakow, Poland – 3 June 2019 – Selvita, a clinical stage drug discovery and development company focused on innovative medicines...

Krakow, Poland – 28 May 2019 – Selvita (WSE: SLV), a clinical stage drug discovery and development company focused on...

- Investigational New Drug (IND) application to conduct a Phase 1 study of selective CDK8 inhibitor SEL120 cleared by U.S....

Krakow, Poland - 16 May 2019 - Selvita today announced that abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for...

About Selvita

Selvita has two primary focus areas:

– to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services and

– as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.

Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries.

We offer drug discovery support at every stage of the early discovery phase up to the preclinical research phase.

In its internal research and development efforts, Selvita focuses on different dimensions of oncology.

The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, in acute myeloid leukemia.

56,8000 PLN More

We are a multicultural and a multinational company employing professionals from all over the world.

Find out who we’re courrently looking for and what we can offer our employees.